Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HCN4 | Q9Y3Q4 | 1/20 | 0.31 |
| ▸ | MC4R | P32245 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20913352 | 0.86 | TP53 (0.35) | TP53SLC6A9LMNANPC1HCN4 | |
| SCHEMBL16036398 | 0.85 | TP53 (0.33) | TP53HCN4MC4RALDH1A1 | |
| SCHEMBL20913345 | 0.84 | TP53 (0.35) | TP53P2RX7MEN1KMT2ASLC6A9 | |
| SCHEMBL20913362 | 0.82 | TP53 (0.33) | TP53P2RX7MEN1KMT2ASLC6A9 | |
| SCHEMBL25957164 | 0.80 | STK17B (0.40) | TP53 | |
| SCHEMBL20926948 | 0.78 | — | — | |
| SCHEMBL30926497 | 0.76 | STK17B (0.37) | TP53P2RX7HCN4 | |
| SCHEMBL16076736 | 0.76 | STK17B (0.37) | TP53P2RX7HCN4 | |
| SCHEMBL20959593 | 0.75 | WNT1 (0.34) | P2RX7 | |
| SCHEMBL20959598 | 0.75 | WNT1 (0.34) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200239486-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | G1 THERAPEUTICS, INC. (US) | 2020-07-30 | — | — | US | disclosed |
| US-10618905-B2 | Pyrimidine-based compounds for the treatment of cancer | G1 THERAPEUTICS, INC. (US) | 2020-04-14 | — | — | US | disclosed |
| US-20190119294-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | G1 THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119294-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | TYMS, TYMP, DPYD | TP53 25/4885P2RX7 1297/4885MEN1 3076/4885 |
| US-20200239486-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | TYMS, TYMP, DPYD | TP53 25/4885P2RX7 1297/4885MEN1 3076/4885 |
| US-10618905-B2 | Pyrimidine-based compounds for the treatment of cancer | TYMS, TYMP, DPYD | TP53 25/4885P2RX7 1297/4885MEN1 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.